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Abstract The role of the NH2-terminus of cytochrome P450
2E1 (CYP2E1) in intracellular targeting was investigated. Two
NH2-terminal CYP2E1 mutants, v(2^29)2E1, lacking the
transmembrane domain, and N++2E1, having Ala2Lys and
Val3Arg substitutions, were generated and expressed in the
H2.35 mouse hepatoma cell line. In cells transfected with both
constructs, a 40 kDa fragment of CYP2E1 (v2E1) was found to
be localized to mitochondria as evidenced from immunofluores-
cence microscopy and subcellular fractionation studies. v2E1
was shown to be a soluble protein localized inside the
mitochondria, displayed catalytic activity when reconstituted
with adrenodoxin and adrenodoxin reductase, and was also
present in mitochondria isolated from rat liver. It is concluded
that in the absence of the hydrophobic NH2-terminal sequence, a
putative mitochondrial import signal is exposed which targets
CYP2E1 to this organelle where it is further processed.
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1. Introduction
Cytochrome P450s (P450s) are a superfamily of enzymes
known to metabolize a wide variety of endogenous and exog-
enous compounds. Most of the eukaryotic P450s are mem-
brane bound enzymes localized in either the endoplasmic re-
ticulum (ER) membrane or inside mitochondria [1,2]. The
highly hydrophobic NH2-terminal domain present in ER lo-
calized P450s serves as a non-cleavable stop-transfer signal
sequence for the cotranslational insertion and anchoring of
the protein in the ER membrane [3,4]. This hydrophobic
NH2-terminus appears to be important in not only membrane
binding but also in ER retention [5,6], although other parts of
the P450 enzyme have also been shown to cause retention [7].
In contrast to microsomal P450s, mitochondrial P450s such as
CYP11A1 (P450scc) and CYP11B (P45011L) [8] are imported
into the mitochondria posttranslationally due to their amphi-
pathic NH2-terminal signal sequence [9]. After removal of the
signal sequence, these P450s become associated with the mi-
tochondrial inner membrane by as yet unknown mechanisms.
The ethanol inducible form of cytochrome P450 (CYP2E1)
is predominantly present in the ER although CYP2E1 has
also been detected in the Golgi apparatus [10], lysosomes
[11] and on the outside of the plasma membrane [12].
CYP2E1 has been suggested to be involved in gluconeogenesis
because of its ability to metabolize ketone bodies such as
acetone [13]. In addition, CYP2E1 metabolizes a wide variety
of small hydrophobic xenobiotics including well-known carci-
nogens and other toxic compounds [13], causes oxidative
stress through the production of reactive oxygen species and
has been implicated in the development of alcoholic liver dis-
ease [14].
In the past decade, many laboratories have considered the
possibility of designing a soluble form of microsomal P450
which could be instrumental in resolving the three-dimension-
al structure of mammalian microsomal P450s. However, these
attempts have been unsuccessful to date and focused on the
removal of the hydrophobic NH2-terminal transmembrane
domain of P450, which is important not only in ER targeting,
binding and retention, but also in the assembly of a catalyti-
cally active P450 and in protein stability [15,16].
In the present study we investigated the role of the NH2-
terminus of rat CYP2E1 in intracellular targeting and mem-
brane association in a hepatoma cell line. NH2-terminally
mutants of CYP2E1 were shown to be imported into mito-
chondria and to be present in a soluble truncated form.
2. Materials and methods
2.1. Expression vectors
Full length rat CYP2E1 cDNA was cloned into the mammalian
expression vector pCMV5 [17]. The CYP2E1 cDNA lacking the cod-
ing sequence for amino acids 2^29 was generated by PCR ampli¢ca-
tion using Pfu DNA polymerase (Stratagene, La Jolla, CA, USA),
primer 1a (5P-GACGAATTCATGTGGAACCTGCCCCCAGGA-3P)
and reverse primer 1b (5P-GACTCTAGATCATGAACGGGGAAT-
GAC-3P). The cDNA for N2E1 containing the Ala2Lys and Va-
l3Arg substitutions was created by PCR ampli¢cation using CYP2E1
cDNA, the mutated primer 2a (5P-GACGAATTCATGAAGAGG-
CTTGGCATCACCATTGCC-3P, bases encoding Lys and Arg are
underlined) and primer 1b. The resulting cDNAs were cloned into
the pCMV5 expression vector. The correct sequence of the inserts
was con¢rmed by DNA sequencing using the ABI Prism Dye Termi-
nator Cycle Sequencing kit from Perkin-Elmer (Norwalk, CT, USA).
2.2. Cell culture and transient transfection
H2.35 cells (mouse SV-40 transformed hepatocytes) were purchased
from the American Type Culture Collection (Rockville, MD, USA).
H2.35 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM, Life Technologies, Rockville, MD, USA) containing 1.0 g/
l glucose supplemented with 4% fetal calf serum, 100 U/ml penicillin,
100 Wg/ml streptomycin and 0.2 WM dexamethasone and maintained
at 37‡C in a humidi¢ed atmosphere of 5% CO2. H2.35 cells were
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transfected with a mixture of plasmid DNA and the cationic lipid
DMRIE-C (Life Technologies) and harvested 24^30 h after the addi-
tion of the DNA/DMRIE-C mix.
2.3. Western blot analysis
Cells were harvested, sonicated in homogenization bu¡er (50 mM
HEPES pH 7.4 containing 0.25 M sucrose and 0.5 mM EDTA) and
centrifuged at 3000Ug for 10 min. The post-nuclear supernatant was
mixed with SDS-PAGE sample bu¡er, proteins were separated on
SDS-PAGE, transferred to nitrocellulose membranes, blocked and
incubated with antibodies as described previously [10].
2.4. Subcellular fractionation
Transfected cells were washed with phosphate bu¡ered saline (PBS),
collected by scraping and homogenized into 2 ml homogenization
bu¡er (50 mM HEPES pH 7.4 containing 0.25 M sucrose, 1 mM
EDTA, 1 Wg/ml antipain, 10 Wg/ml leupeptin and 1 mM PMSF).
The homogenate was centrifuged at 3000Ug for 10 min and 2 ml
post-nuclear supernatant was layered on top of a discontinuous su-
crose gradient and centrifuged as described [18]. Fractions (1 ml) were
collected from bottom to top after puncturing the bottom of the tube.
Protein was determined after acid precipitation according to Peterson
[19] and samples were analyzed by Western blot.
2.5. Membrane association and topology
v(2^29)2E1 transfected cells were homogenized and the post-nu-
clear supernatant was prepared as described above. The mitochondrial
fraction was prepared by centrifugation of the post-nuclear superna-
tant at 10 000Ug for 15 min. Membrane association of v2E1 was
investigated by sodium deoxycholate (NaDOC) treatment. The mito-
chondrial fraction was resuspended in 50 mM Tris-HCl bu¡er pH 7.4
containing 100 mM KCl and 5 mM MgCl2 at a protein concentration
of 1 mg/ml and incubated in the presence of 0.05% NaDOC for 30
min on ice. The particulate and soluble fractions were separated by
centrifugation at 10 000Ug for 15 min and both fractions were ana-
lyzed by Western blot.
Membrane topology was determined by the protease protection
assay. Brie£y, the mitochondrial fraction was diluted in 50 mM
Tris-HCl bu¡er pH 8.0 containing 10 mM CaCl2 and 150 mM
NaCl to a protein concentration of 1 mg/ml. The samples were in-
cubated with proteinase K (83 Wg/ml) in the presence or absence of
0.05% NaDOC at 37‡C for 30 min. The reaction was terminated by
the addition of PMSF (¢nal concentration 10 mM) and the samples
were analyzed by Western blot.
2.6. Immuno£uorescence microscopy
Cells grown and transfected on glass coverslips were washed three
times in PBS, ¢xed in 2% formaldehyde in PBS for 10 min and per-
meabilized with 0.2% Triton X-100 in PBS for 10 min. After blocking
in 10% fetal bovine serum in PBS for 2.5 h, the cells were incubated
with anti-CYP2E1 antibodies (1:5000 dilution) in 3% bovine serum
albumin (BSA) in PBS for 90 min followed by FITC conjugated goat
anti-rabbit antibodies (1:500 dilution) in 3% BSA in PBS for 90 min.
For double immunostaining, FITC conjugated goat anti-rabbit and
TRITC conjugated goat anti-mouse antibodies were used to visualize
CYP2E1 and mitochondrial Hsp70 (mHsp70, A⁄nity Bioreagents
Inc., Goldon, CO, USA) related immunoreactivity respectively.
Stained cells were carefully mounted with a drop of Vecta-Shield
(Vector Laboratories, Burlingame, CA, USA) on a glass slide. The
glass slides were viewed under an Olympus BX60 microscope
equipped with Olympus PM20 camera (Tokyo, Japan).
2.7. Catalytic activity
The catalytic activity of v2E1 was determined by monitoring the
formation of 6-hydroxy-chlorzoxazone essentially as described [10].
Mitochondria from cells transfected with v(2^29)2E1 and empty plas-
mid were isolated and disrupted by sonication (three bursts of 10 s
with 30 s intervals) on ice. The incubation mixture consisted of 100 Wg
sonically disrupted mitochondria, 50 WM chlorzoxazone, a NADPH
generating system (0.2 mM NADPH, 2.0 mM glucose 6-phosphate
and 3 U/ml glucose 6-phosphate dehydrogenase), 1 nmol adrenodoxin
(Adx), 0.1 nmol adrenodoxin reductase (AdR), kindly supplied by
Prof. Rita Bernhardt, University of Saarbru«cken, Germany, and
50 mM phosphate bu¡er pH 7.4 in a ¢nal volume of 0.25 ml. After
30 min the reaction was terminated by the addition of orthophospho-
ric acid and an internal standard (0.04 Wg acetaminophen) was added.
After extraction, the samples were analyzed by HPLC equipped with
an amperometric detector.
2.8. Isolation of rat liver mitochondria
Untreated male Sprague-Dawley rats were anesthetized and killed
by decapitation. Livers were perfused with PBS, removed from the
animal and mitochondria were prepared according to Boyer et al. [20]
and additionally puri¢ed by sedimentation through a discontinuous
sucrose gradient [21]. Mitochondria puri¢ed in this way were shown
to be heavily enriched in mitochondrial marker protein (20-fold en-
richment of mHsp70) and essentially devoid of microsomal contami-
nation (less than 0.5% of NADPH cytochrome P450 reductase).
3. Results
3.1. Transient expression and characterization of the
CYP2E1 mutants
The two NH2-terminal CYP2E1 mutants, v(2^29)2E1 and
N2E1, together with wt2E1 (Fig. 1A shows the NH2-termi-
nal amino acid sequences) were transfected into H2.35 cells.
As expected, wt2E1 produced the full length CYP2E1 protein
with an apparent molecular weight of 52 kDa (Fig. 1B),
whereas in cells transfected with empty plasmid (mock) no
protein was observed, demonstrating that this cell line does
not express signi¢cant amounts of endogenous CYP2E1. In
cells transfected with N2E1, a band with similar mobility as
wt2E1 was observed together with a minor band around
Fig. 1. Transient expression of wt2E1, N2E1 and v(2^29)2E1 in
H2.35 cells. A: NH2-terminal amino acid sequence of the constructs
used. Amino acids which were substituted are represented in a black
box and amino acids which were deleted are represented by an
empty space. The putative mitochondrial targeting signal is boxed,
with the hydrophobic amino acids (localized on one side of the K-
helix) in gray boxes, hydrophilic residues in white and positively
charged amino acids indicated with +. B: The post-nuclear superna-
tants isolated from H2.35 transfected with either wt2E1, empty plas-
mid (mock), N2E1 or v(2^29)2E1 were analyzed by using
CYP2E1 speci¢c antibodies. C: Post-nuclear supernatants analyzed
by antibodies speci¢cally recognizing the COOH-terminal ¢ve amino
acids of CYP2E1. The arrow indicates the full length CYP2E1 and
the arrowhead indicates the 40 kDa band v2E1.
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40 kDa (Fig. 1B, arrowhead). In v(2^29)2E1 transfected cells,
no protein with the predicted size around 50 kDa could be
detected. However, as observed for N2E1, a CYP2E1 im-
munoreactive protein of about 40 kDa was seen which implied
the presence of a truncated form of CYP2E1 (v2E1). Anti-
peptide antibodies raised against the terminal ¢ve amino acids
of the COOH-terminus of human CYP2E1 [22] recognized
wt2E1, the full length N2E1 (Fig. 1C, arrow) and also
v2E1 (Fig. 1C, arrowhead). This demonstrated that the
COOH-terminus of v2E1 was identical to the COOH-termi-
nus of wt2E1 and that v2E1 was an NH2-terminally truncated
CYP2E1 form.
3.2. Intracellular localization of v2E1
The intracellular distribution of the expressed wt2E1,
N2E1 and v2E1 was examined by indirect immuno£uores-
cence microscopy (Fig. 2). Cells transfected with wt2E1 dis-
played a reticular staining pattern throughout the cytoplasm
typically observed for ER proteins, con¢rming the expected
ER localization for wt2E1 (Fig. 2A). In N2E1 transfected
cells, the same reticular staining pattern was observed indicat-
ing that the majority of the protein is associated with the ER
(Fig. 2C). Cells transfected with v(2^29)2E1 displayed an im-
muno£uorescent staining being con¢ned to worm-like struc-
tures mainly localized in the perinuclear region of the cell
(Fig. 2B). This staining pattern is observed for proteins asso-
ciated with the mitochondria, suggesting a mitochondrial lo-
calization for v2E1. Once again, no signi¢cant staining could
be observed in cells transfected with empty plasmid which
demonstrated that these cells are devoid of signi¢cant
amounts of endogenous CYP2E1 (Fig. 2D). In order to
further establish the mitochondrial localization of v2E1,
Fig. 2. Immuno£uorescence microscopy of hepatoma cells expressing wt2E1, v2E1 and N2E1. H2.35 cells were grown and transfected with
(A) wt2E1, (B) v(2^29)2E1, (C) N2E1 and (D) empty plasmid on glass coverslips and after ¢xation and permeabilization were incubated
with CYP2E1 speci¢c antibodies followed by FITC conjugated anti-rabbit IgG as described in Section 2.
Fig. 3. Association of v2E1 with mitochondria revealed by immuno£uorescent microscopy. v(2^29)2E1 transfected cells were double stained
with (A) CYP2E1 speci¢c antibodies visualized by FITC conjugated anti-rabbit IgG and (B) mitochondrial Hsp70 antibodies visualized by
TRITC conjugated anti-mouse IgG. As seen, both proteins are localized to the same structures.
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v(2^29)2E1 transfected cells were double immunostained with
a monoclonal antibody recognizing mHsp70, a protein
residing in the mitochondria, and with a CYP2E1 speci¢c
antiserum. As shown in Fig. 3, the staining pattern observed
with the CYP2E1 speci¢c antiserum recognizing v2E1 (Fig.
3A) was identical to that observed with the mHsp70 speci¢c
antibodies (Fig. 3B), thereby revealing the mitochondrial
localization of this protein.
The intracellular distribution of v2E1 was also assessed
by subcellular fractionation of cells transfected either with
v(2^29)2E1 or N2E1 on discontinuous sucrose gradients.
Fig. 4A shows that in cells transfected with v(2^29)2E1,
v2E1 was recovered solely in the fractions which also con-
tained the mitochondrial marker. In N2E1 transfected cells,
the full length N2E1 was recovered in fractions where
the ER marker was present, which con¢rmed its ER local-
ization, and was well separated from v2E1 present in the
mitochondrial fractions (Fig. 4B).
3.3. Membrane association and topology of v2E1
The membrane association of v2E1 was investigated
by treatment of the mitochondrial fraction obtained from
v(2^29)2E1 transfected cells with 0.05% NaDOC, known to
release soluble proteins into the soluble fraction but not mem-
brane bound proteins. Nearly all v2E1 was recovered in the
soluble fraction (S) (Fig. 5A). The soluble mHsp70 was used
as a control and was also shown to be present in the soluble
fraction (Fig. 5A). NaDOC treatment of the microsomal frac-
tion of cells transfected with wt2E1 resulted in the recovery of
integral membrane proteins such as wt2E1 and NADPH cy-
tochrome P450 reductase in the particulate fraction (data not
shown). In order to con¢rm that v2E1 was indeed a soluble
protein, mitochondria were disrupted by sonication (three
bursts of 15 s each with 30 s intervals) [8]. The membranous
and soluble fractions were separated by centrifugation and
samples were analyzed by Western blotting. About 85% of
the v2E1 present in the mitochondria was recovered in the
soluble fraction, indicating that, as observed in the NaDOC
experiments, v2E1 was a soluble protein.
The mitochondrial pellet of cells expressing v2E1 was also
treated with proteinase K in order to determine the topology
of v2E1 in the mitochondria (Fig. 5B). In non-permeabilized
mitochondria v2E1 was not digested by proteinase K, how-
ever when 0.05% NaDOC was added all v2E1 was digested.
The mitochondrial matrix protein mHsp70 displayed identical
behavior. These observations demonstrate that v2E1 is a solu-
ble protein and is located inside the mitochondria.
3.4. Rat liver mitochondria
In order to investigate if v2E1 was present in vivo, mito-
Fig. 4. Subcellular distribution of v2E1 and N2E1 in H2.35 cells.
A: Cells transfected with v(2^29)2E1 express v2E1 which is recov-
ered in the same fractions as the mitochondrial marker mHsp70. B:
Cells transfected with N2E1 express both full length N2E1
which is recovered in the fractions containing the ER marker pro-
tein disul¢de isomerase (PDI) and v2E1 which is recovered in the
mitochondrial fractions. The fraction containing the highest amount
of each protein was set at 100% and the protein content of the oth-
er fractions was related to this value. Relative amounts of protein
were quanti¢ed by densitometric analysis. Fractions were harvested
from the bottom (fraction number 1) to the top (fraction number
12) of the gradient.
Fig. 5. Intramitochondrial localization and membrane association of
v2E1. A: The mitochondrial fraction of v(2^29)2E1 transfected cells
was incubated in the presence of 0.05% NaDOC and the particulate
(P) and soluble (S) fractions were isolated and analyzed for both
v2E1 and the soluble mitochondrial protein mHsp70. B: The mito-
chondrial fraction of cells transfected with v(2^29)2E1 was incu-
bated with or without proteinase K (Prot K) and NaDOC as indi-
cated. After digestion, samples were analyzed for v2E1. The results
revealed that v2E1 was localized inside the mitochondria. C: Pres-
ence of v2E1 in mitochondria isolated from rat liver. v2E1 was re-
covered solely in the soluble fraction (S) after NaDOC treatment of
mitochondria from livers isolated from control rats (con). v2E1 ex-
pressed in H2.35 cells was added as a standard in the last lane.
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chondria, essentially devoid of ER contamination, were iso-
lated from control rat liver. The rat liver mitochondrial frac-
tion was examined by Western blot using the CYP2E1 speci¢c
antiserum. As shown in Fig. 5C, the mitochondrial fraction
puri¢ed from rat liver contained a band which was identical to
v2E1 obtained from v(2^29)2E1 transfected cells. Moreover,
v2E1 present in rat liver mitochondria was also recovered in
the soluble fraction (S) after NaDOC treatment. This demon-
strated that v2E1 is also present in rat liver mitochondria as a
soluble protein.
3.5. Catalytic activity of v2E1
The catalytic activity of v2E1 was determined by monitor-
ing the formation of 6-hydroxy-chlorzoxazone in mitochon-
dria disrupted by sonication and reconstituted with Adx and
AdR. Mitochondria isolated from v2E1 expressing cells dis-
played signi¢cantly higher catalytic activity than mitochondria
isolated from mock transfected cells when reconstituted with
both Adx and AdR (Table 1). When Adx and AdR were
omitted from the incubation mixture only low levels of 6-
hydroxy-chlorzoxazone could be detected, indicating that the
catalytic activity of v2E1 is strongly supported by these two
mitochondrial electron transport proteins. Similar results were
obtained in three independent transfection experiments.
4. Discussion
Although it has been described that CYP2E1 is mainly
localized in the ER membrane, small amounts of CYP2E1
are also found in the Golgi apparatus, in lysosomes and on
the outside of the plasma membrane. Here, we describe the
presence of an NH2-terminally truncated soluble form of
CYP2E1, v2E1, in yet another cellular compartment, the mi-
tochondria. v2E1 was also shown to be catalytically active
and to be present in mitochondria isolated from rat liver.
The majority of the proteins that are posttranslationally
imported into mitochondria contain an NH2-terminal amphi-
pathic signal sequence, which is usually removed after import
[23,24]. The basic requirements for this mitochondrial target-
ing sequence are about 20^60 amino acid residues with several
positive charges, almost no negative ones and several hy-
droxylated residues [25,26]. The targeting sequence is assumed
to be able to form an amphipathic K-helix and through its
positive charges able to bind to the negatively charged surface
of the mitochondrial import machinery which is located both
on the outer and inner membrane of the mitochondria [27]. It
has been demonstrated that mitochondrial P450s are imported
into mitochondria through their NH2-terminal signal se-
quence [8,9]. There are, however, reports describing mitochon-
drial targeting sequences which are localized at the COOH-
terminus or inside the protein [28,29].
We found that after removal of the hydrophobic NH2-ter-
minal transmembrane domain of CYP2E1, the resulting trun-
cated protein is targeted to and imported into mitochondria.
This indicates that removal of the hydrophobic transmem-
brane domain exposes a putative mitochondrial import signal.
Examination of the NH2-terminal amino acid sequence of
v(2^29)2E1 reveals that there is a region rich in positively
charged amino acids (residues 53^64) which is able to form
an amphipathic K-helix and therefore could potentially serve
as a mitochondrial targeting signal (Fig. 1A). We suggest that
after mitochondrial import the potential targeting sequence is
removed thereby generating the 40 kDa fragment v2E1. When
two positively charged amino acids were introduced into the
NH2-terminus of CYP2E1 the same mitochondrially localized
v2E1 could be observed, although the majority of the trans-
lated protein was the expected full length form which was
located in the ER. The reason for the mitochondrial import
and formation of v2E1 from a small fraction of N2E1
remains unclear, but a similar mechanism as postulated for
the mitochondrial import of a truncated form of CYP1A1
could well be operating here [30]. It was shown that a fraction
of the nascent CYP1A1 chains were able to escape ER inser-
tion and that these chains, once localized in the cytosol, were
cleaved by an unknown cytosolic endoprotease. After removal
of the NH2-terminus, a cryptic mitochondrial targeting signal
was exposed and the truncated CYP1A1 was imported into
mitochondria. The introduction of the two positive charges in
CYP2E1 might possibly compromise ER targeting, thereby
allowing for the removal of the hydrophobic transmembrane
domain and subsequent exposure of the mitochondrial target-
ing signal.
It has been demonstrated that speci¢c pathways exist for
import and processing of mitochondrial P450s in di¡erent
tissues [31]. It was shown that in vitro translated precursors
of CYP11A1 and CYP11B are only imported and processed
to their mature form in mitochondria originating from ster-
oidogenic tissues. v2E1 was only detected when v(2^29)2E1
and N2E1 were transfected in a cell line from hepatocyte
origin, whereas no v2E1 could be observed when these
CYP2E1 mutants were transfected into either COS-1 cells or
a ¢broblast cell line (data not shown). This suggests that
mitochondrial import of these NH2-terminal CYP2E1 mu-
tants is also dependent on the cell type used.
v2E1 was shown to display catalytic activity when recon-
stituted with the mitochondrial electron transport proteins
Adx and AdR. These two enzymes were essential for generat-
ing a signi¢cant level of catalytic activity. A similar Adx/AdR
dependence was reported for the catalytic activity of an NH2-
terminally truncated CYP1A1, which was also shown to dis-
play a di¡erent substrate speci¢city compared to microsomal
CYP1A1 [32]. An altered substrate speci¢city of v2E1,
although demonstrating chlorzoxazone 6-hydroxylase activity,
can at this point not be excluded. The physiological implica-
tions of the presence of a catalytically active truncated
CYP2E1 present inside mitochondria are unknown, but the
potential ethanol dependent induction of this protein and its
capability to cause oxidative stress are interesting in light of
the fact that mitochondrial swelling and apoptosis are early
events in alcoholic liver disease [14,33].
In conclusion, we have for the ¢rst time described a soluble
Table 1
Catalytic activities of mitochondria isolated from H2.35 cells trans-
fected with empty plasmid (mock) and with v(2^29)2E1
pmol 6-hydroxy-chlorzoxazone/min/mg protein
3Adx/AdR +Adx/AdR
Mock 0.23 0.50
v2E1 0.37 2.09
Sonically disrupted mitochondria were assayed in the presence (+)
or absence (3) of Adx and AdR for the 6-hydroxylation of chlor-
zoxazone as described in Section 2. Results shown are the average
of two determinations and represent three independent transfections.
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catalytically active form of ER derived P450, which could
perhaps be instrumental in obtaining a crystal structure.
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